CN117120080A - 克隆性新抗原的鉴定及其用途 - Google Patents

克隆性新抗原的鉴定及其用途 Download PDF

Info

Publication number
CN117120080A
CN117120080A CN202280026453.4A CN202280026453A CN117120080A CN 117120080 A CN117120080 A CN 117120080A CN 202280026453 A CN202280026453 A CN 202280026453A CN 117120080 A CN117120080 A CN 117120080A
Authority
CN
China
Prior art keywords
tumor
clonal
mutation
cells
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280026453.4A
Other languages
English (en)
Chinese (zh)
Inventor
安德鲁·罗思
马克西米利安·普林茨·祖·萨尔姆-霍斯特马尔
陈丰春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achilles Therapeutics PLC
Original Assignee
Achilles Therapeutics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achilles Therapeutics UK Ltd filed Critical Achilles Therapeutics UK Ltd
Publication of CN117120080A publication Critical patent/CN117120080A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
CN202280026453.4A 2021-04-01 2022-04-01 克隆性新抗原的鉴定及其用途 Pending CN117120080A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104715.4A GB202104715D0 (en) 2021-04-01 2021-04-01 Identification of clonal neoantigens and uses thereof
GB2104715.4 2021-04-01
PCT/EP2022/058793 WO2022207925A1 (en) 2021-04-01 2022-04-01 Identification of clonal neoantigens and uses thereof

Publications (1)

Publication Number Publication Date
CN117120080A true CN117120080A (zh) 2023-11-24

Family

ID=75883641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026453.4A Pending CN117120080A (zh) 2021-04-01 2022-04-01 克隆性新抗原的鉴定及其用途

Country Status (10)

Country Link
US (2) US11504398B2 (enExample)
EP (1) EP4313125A1 (enExample)
JP (1) JP2024513781A (enExample)
KR (1) KR20230165259A (enExample)
CN (1) CN117120080A (enExample)
AU (1) AU2022251011A1 (enExample)
CA (1) CA3213222A1 (enExample)
GB (1) GB202104715D0 (enExample)
IL (1) IL306136A (enExample)
WO (1) WO2022207925A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
EP4681208A1 (en) 2023-03-17 2026-01-21 T-Cypher Bio Ltd Prediction of immunogenicity
GB202307096D0 (en) 2023-05-12 2023-06-28 Achilles Therapeutics Uk Ltd Method
WO2024256485A1 (en) 2023-06-15 2024-12-19 Achilles Therapeutics Uk Limited Identification of neoantigen peptides
GB202407727D0 (en) 2024-05-31 2024-07-17 Ucl Business Ltd Reporters constructs, systems and assays

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882867A1 (en) 2012-08-10 2015-06-17 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
US11725237B2 (en) * 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6740127B2 (ja) 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
ES2836273T3 (es) * 2015-04-27 2021-06-24 Cancer Research Tech Ltd Método para el tratamiento del cáncer
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP6904953B2 (ja) * 2015-12-03 2021-07-21 アレス トレーディング ソシエテ アノニム 細胞クローン性を決定する方法
CA3050109A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
WO2018170578A1 (en) * 2017-03-20 2018-09-27 Ontario Institute For Cancer Research (Oicr) Cancer risk based on tumour clonality
EP3651791A1 (en) * 2017-07-14 2020-05-20 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
EP3622522A1 (en) * 2017-12-01 2020-03-18 Illumina, Inc. Methods and systems for determining somatic mutation clonality
IL259392A (en) * 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
US11189361B2 (en) * 2018-06-28 2021-11-30 International Business Machines Corporation Functional analysis of time-series phylogenetic tumor evolution tree
CN111785322A (zh) * 2019-12-30 2020-10-16 杭州慕谷基因科技有限公司 一种结肠腺癌基因组变异与肿瘤进化关系的研究方法
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205147D0 (en) * 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof

Also Published As

Publication number Publication date
WO2022207925A1 (en) 2022-10-06
GB202104715D0 (en) 2021-05-19
IL306136A (en) 2023-11-01
US11504398B2 (en) 2022-11-22
CA3213222A1 (en) 2022-10-06
JP2024513781A (ja) 2024-03-27
KR20230165259A (ko) 2023-12-05
US12548651B2 (en) 2026-02-10
US20230071113A1 (en) 2023-03-09
AU2022251011A1 (en) 2023-10-05
EP4313125A1 (en) 2024-02-07
US20220323499A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US11504398B2 (en) Identification of clonal neoantigens and uses thereof
Miao et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Garofalo et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Sanborn et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination
Kiyotani et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
Giannakis et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma
US20200232040A1 (en) Neoantigens and uses thereof for treating cancer
CN110913896A (zh) 肿瘤中hla等位基因的分析及其用途
Morazán-Fernández et al. In silico pipeline to identify tumor-specific antigens for cancer immunotherapy using exome sequencing data
US20220081724A1 (en) Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer
US20250218535A1 (en) Identification of clonal neoantigens and uses thereof
Li et al. Integrated genomic characterization of the human immunome in cancer
Lo et al. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
Barroux et al. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma
Xie et al. Single-cell analysis of tumor microenvironment immune homeostasis and identification of prognostic biomarkers in head and neck squamous cell carcinoma
US20250239349A1 (en) Systems and methods for determining t-cell cross-reactivity between antigens
JP2025534267A (ja) 対立遺伝子特異的発現
Hu et al. Pan-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
Gurjao Leveraging passenger mutations to guide cancer treatment and prevention
CA3268552A1 (en) Allele specific expression
Xia Improving Neoantigen Prioritization Methods for Personalized Cancer Vaccines
Ladd et al. Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients: S. Ladd et al.
Moore et al. Lack of TGFβ signaling competency predicts conversion of immune poor cancer to immune rich and response to checkpoint blockade.
Moore et al. A conserved subset of cold tumors responsive to immune checkpoint blockade
Borden Immune Recognition and Sculpting of Neoantigens in Human Tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination